Bioidentical hormones market set for faster growth through 2030

The global bioidentical hormones market is projected to rise from $7.97 billion in 2025 to $8.47 billion in 2026, with TBRC forecasting continued expansion to $10.49 billion by 2030. Demand is being driven by personalized medicine, aging populations and broader use of hormone therapy technologies.

Why it matters: - The bioidentical hormones market is moving from niche hormone therapy into a broader personalized medicine segment. - Rising demand for tailored treatments could expand use in menopause, andropause and other hormone-related conditions. - The market’s growth may also accelerate adoption of safer, more patient-specific hormone replacement approaches.

What happened: - The Business Research Company said the global bioidentical hormones market will grow from $7.97 billion in 2025 to $8.47 billion in 2026. - TBRC projected the market will reach $10.49 billion by 2030. - The research was released Nov. 5, 2026, from London. - TBRC said the market is being shaped by demand for hormone therapy and personalized medicine.

The details: - TBRC estimated 6.3% CAGR growth from 2025 to 2026. - TBRC forecast 5.5% CAGR growth through 2030. - Drivers of historical growth include rising menopausal and andropausal symptoms, greater awareness of hormone imbalance treatments, more specialty hormone clinics, wider access to compounding pharmacy services and growing clinical acceptance. - Future growth is expected to come from personalized medicine, demand for safer hormone therapies, an aging population, digital health monitoring in hormone replacement therapy and expanding clinical research. - Key trends include wider acceptance of personalized hormone replacement therapies, increased use of compounded bioidentical hormone formulations, more transdermal delivery systems, more patient-specific dosing strategies and a stronger focus on safety and efficacy. - Bioidentical hormones are designed to mirror the chemical structure of hormones naturally produced by the human body. - These hormones are primarily used in hormone replacement therapy to address hormonal imbalances and deficiencies. - Common uses include easing hot flashes, night sweats, mood fluctuations and reduced libido. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - TBRC said its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report sample is available here. - The full report is available here.

Between the lines: - The forecast points to a market gaining traction as hormone therapy shifts toward more individualized care. - The emphasis on digital monitoring and transdermal delivery suggests the category is evolving beyond traditional prescription models. - The inclusion of stronger safety and efficacy messaging indicates the market is still competing on clinical trust as well as growth.

What's next: - TBRC expects personalized medicine and clinical validation to remain the main growth themes through 2030. - Asia-Pacific’s faster growth could narrow the gap with North America if demand and healthcare adoption continue to rise. - The market will likely keep adding product and delivery innovations tied to patient-specific dosing and monitoring.